^
    Back
    Association details:
    Biomarker:EGFR L861Q
    Cancer:Lung Adenocarcinoma
    Drug:Ameile (aumolertinib) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Acta Pharmacol Sin
    Title:

    Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations

    Excerpt:
    Radiological responses of a 62-year-old female patient with EGFR L861Q mutant stage IV lung adenocarcinoma after 16-week treatment of aumolertinib 110 mg orally once daily combined with chemotherapy (700 mg pemetrexed disodium, 500 mg carboplatin).
    Secondary therapy:
    carboplatin + pemetrexed
    DOI:
    https://doi.org/10.1016/j.apsb.2023.03.007